Cargando…
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
RAS genes are the most frequently mutated oncogenes and play critical roles in the development and progression of malignancies. The mutation, isoform (KRAS, HRAS, and NRAS), position, and type of substitution vary depending on the tissue types. Despite decades of developing RAS‐targeted therapies, o...
Autores principales: | Yang, Hang, Zhou, Xinyi, Fu, Dongliang, Le, Chenqin, Wang, Jiafeng, Zhou, Quan, Liu, Xiangrui, Yuan, Ying, Ding, Kefeng, Xiao, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859734/ https://www.ncbi.nlm.nih.gov/pubmed/36316602 http://dx.doi.org/10.1002/cac2.12377 |
Ejemplares similares
-
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022) -
Offline: Reasons for hope
por: Horton, Richard
Publicado: (2020) -
Successes, Failures and Hopes in Cancer Chemotherapy
por: Wilkinson, P.
Publicado: (1981) -
Targeting the “undruggable” RAS - new strategies - new hope?
por: Mörchen, Britta, et al.
Publicado: (2019) -
New Agents in Development for Sepsis: Any Reason for Hope?
por: Vignon, Philippe, et al.
Publicado: (2020)